ELISpot 和 FluoroSpot 检测市场 - 全球产业规模、份额、趋势、机会、预测：按产品、应用、最终用户、地区和竞争对手划分，2021-2031 年

全球 ELISpot 和 FluoroSpot 检测市场预计将从 2025 年的 10.6 亿美元成长到 2031 年的 15.1 亿美元，复合年增长率为 5.96%。

这些高灵敏度的免疫检测技术旨在在单细胞层级检测和定量细胞激素分泌细胞，为免疫监测提供关键数据。该市场的主要成长要素是结核病等感染疾病在全球范围内日益严重的负担以及癌症免疫疗法研究的扩展，这两者都需要对细胞免疫反应进行精确评估。此外，疫苗研发计画的快速进展也是一个重要的驱动力，推动了临床试验中对这些检测方法的需求。世界卫生组织（WHO）报告称，2024年全球新增结核病病例约830万例，凸显了对干扰素-γ释放试验等精准诊断工具的迫切需求。

儘管市场需求强劲，但先进检测试剂盒和自动化检测设备的高成本构成了重大挑战。此外，这些方法的技术复杂性也加剧了这种经济障碍，因为数据分析需要专业人员操作，这限制了小规模实验室和资源匮乏地区采用这些先进技术。因此，这些因素可能会阻碍市场的整体扩张。

市场驱动因素

癌症免疫疗法和T细胞反应研究的快速进展正在推动全球ELISpot和FluoroSpot检测市场的发展。这些检测方法对于监测临床试验中的免疫反应至关重要，尤其是在评估CAR-T细胞疗法和查核点抑制剂的疗效方面。随着研究人员积极探索新的靶点，对用于定量细胞激素分泌细胞的高灵敏度工具的需求日益增长。越来越多的监管结果要求进行严格的免疫监测，进一步推动了这一趋势。例如，癌症研究所的《2024年影响报告》显示，仅在过去一年，就有13种新的免疫疗法获得了FDA的核准，这一激增直接凸显了对精准技术的需求，以支持不断扩大的开发平臺。

同时，疫苗研发日益受到重视，这成为一股重要的驱动力，也催生了对强大平台的需求，以便能够测量除简单抗体反应之外的细胞免疫。向T细胞评估的转变已使这些检测方法成为感染疾病疫苗研究的关键基准。领先的生物技术公司正在投入大量预算来支持这项创新。正如Moderna公司在其2024年第二季财报新闻稿中所述，该公司预计2024年全年研发支出约为45亿美元，这反映出其对利用这些工具的专案投入了大规模资金。此外，整个产业的投资成长也支持了这一发展。根据欧洲製药工业协会联合会（EFPIA）的数据，欧洲製药业预计将在2024年投资550亿欧元用于研发，这凸显了推动这些检测方法应用的巨额资金投入。

市场挑战

自动化检测系统的高成本以及试剂盒的持续投入是全球ELISpot和FluoroSpot检测市场扩张的主要障碍。小规模的实验室和诊断机构，尤其是在感染疾病负担最重的欠发达地区，往往缺乏足够的资金来部署这些昂贵的平台。这种经济上的差距迫使许多机构依赖准确度较低的传统方法，限制了这些先进、高灵敏度技术的潜在市场。

生命科学领域整体资金筹措困难加剧了这个挑战，直接影响了购买资本设备的能力。根据 MassBio 统计，2025 年上半年生物技术领域的创业投资较去年同期下降超过 17%。资金筹措减少迫使实验室推迟设备升级，并避免投资昂贵的诊断工具。因此，设备高昂的初始成本加上外部投资的减少，导致市场渗透困难，减缓了这些检测方法的整体普及速度。

市场趋势

将人工智慧驱动的演算法整合到自动化斑点分析中，正从根本上改变全球市场数据解读的基础。实验室正越来越多地采用深度学习模型来标准化斑点计数，从而消除手动显微镜检查中固有的操作者间差异。这种转变在高通量萤光斑点检测中尤其关键，因为这类检测需要复杂的计算分解来区分重迭的频谱讯号。主要产业参与者透过数位转型获利，其财务表现也印证了这些数位工具的商业性可行性。根据Revvity公司2025年2月发布的截至2024年12月29日的年度报告，其生命科学部门的软体收入增加了2,250万美元，凸显了客户对能够简化复杂免疫学工作流程的数位分析平台的投资激增。

多重流式点阵技术在多功能免疫分析中的广泛应用，标誌着其在技术上相较于传统的单次分析ELISpot方法取得了决定性的进步。研究人员优先考虑能够同时检测单一细胞中多种细胞激素的检测方法，从而能够详细表征T细胞的多功能性，而T细胞是感染疾病和肿瘤研究中重要的保护性指标。这种对高资讯量数据的需求，正推动蛋白质分析工具製造商的持续收入成长。根据Bio-Techne公司于2025年8月发布的2025年第四季财报，其蛋白质科学部门的净销售额达到2.265亿美元，较去年同期成长6%。这凸显了市场对多重试剂和检测平台（多变量免疫分析所必需的）的强劲需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球ELISpot与FluoroSpot检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类别（检测试剂盒、分析仪器、相关产品）
  • 透过应用（诊断、调查）
  • 依最终用户（医院/诊所、研究机构、生物製药公司、合约研究组织）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美ELISpot与FluoroSpot检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲ELISpot与FluoroSpot检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区ELISpot与FluoroSpot检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲ELISpot和FluoroSpot侦测的市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲ELISpot与FluoroSpot检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球ELISpot与FluoroSpot检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Becton, Dickinson and Company
• U-CyTech BV
• Cellular Technology Limited
• Mabtech AB
• Abcam Limited
• AID AUTOIMMUN DIAGNOSTIKA GMBH
• Mikrogen GmbH
• Bio-Connect Group
• Oxford Immunotec USA, Inc.
• Bio-Techne Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global ELISpot and FluoroSpot Assay Market is projected to expand from USD 1.06 billion in 2025 to USD 1.51 billion by 2031, reflecting a compound annual growth rate of 5.96%. These high-sensitivity immunoassay technologies are designed to detect and quantify cytokine-secreting cells at the single-cell level, providing essential data for immunological monitoring. The market is primarily driven by the increasing global burden of infectious diseases, such as tuberculosis, and the growing field of cancer immunotherapy research, both of which require precise evaluation of cellular immune responses. Additionally, the rapid pace of vaccine development programs acts as a significant catalyst, boosting demand for these assays in clinical trials. In 2024, the World Health Organization reported approximately 8.3 million new tuberculosis diagnoses worldwide, underscoring the critical need for accurate diagnostic tools like interferon-gamma release assays.

Despite strong market demand, the high cost associated with advanced assay kits and automated detection instruments poses a significant challenge. This financial barrier is often exacerbated by the technical complexity of the methods, which require skilled personnel for data analysis, thereby limiting the adoption of these sophisticated technologies in smaller research laboratories and resource-constrained settings. Consequently, these factors potentially hinder the overall expansion of the market.

Market Driver

The rapid growth of cancer immunotherapy and T-cell response research serves as a primary engine for the Global ELISpot and FluoroSpot Assay Market. These assays have become indispensable for monitoring immune responses in clinical trials, particularly for evaluating the efficacy of CAR-T cell therapies and checkpoint inhibitors. As researchers actively pursue new targets, the need for high-sensitivity tools to quantify cytokine-secreting cells has intensified. This momentum is supported by increasing regulatory achievements that demand rigorous immune monitoring. For instance, the Cancer Research Institute's '2024 Impact Report' noted 13 new FDA approvals for immunotherapy treatments in the past year alone, a surge that directly amplifies the necessity for precise technologies to support these expanding developmental pipelines.

Simultaneously, the intensified focus on vaccine development acts as a critical driver, necessitating robust platforms for measuring cellular immunity beyond simple antibody responses. The shift toward T-cell assessment has positioned these assays as essential benchmarks in infectious disease vaccine research. Major biotechnology firms are maintaining significant budgets to sustain this innovation. As reported in Moderna, Inc.'s 'Second Quarter 2024 Financial Results' press release, the company anticipated full-year 2024 research and development expenses to be approximately $4.5 billion, reflecting massive capital allocation toward programs utilizing these tools. Furthermore, broader sector investment supports this growth; according to the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical industry invested an estimated €55,000 million in R&D in Europe in 2024, highlighting the financial commitment driving assay adoption.

Market Challenge

The high cost of automated detection instruments and the recurring expense of assay kits present a substantial barrier to the expansion of the Global ELISpot and FluoroSpot Assay Market. Smaller research laboratories and diagnostic facilities, particularly in developing regions where infectious disease burdens are highest, often lack the capital budget required to procure these expensive platforms. This financial disparity forces many institutions to continue relying on older, less precise methodologies, thereby restricting the addressable market for these advanced high-sensitivity technologies.

The challenge is further intensified by the tightening of financial resources within the broader life sciences sector, which directly impacts purchasing power for capital equipment. According to MassBio, in 2025, venture capital investment in the biotechnology sector declined by more than 17% during the first half of the year compared to the same period in 2024. This contraction in available funding compels laboratories to defer upgrades and avoid investing in premium diagnostic tools. Consequently, the combination of steep upfront instrument costs and reduced external investment creates a difficult environment for market penetration, slowing the overall adoption of these assays.

Market Trends

The integration of AI-driven algorithms for automated spot analysis is fundamentally reshaping data interpretation within the global market. Laboratories are increasingly deploying deep learning models to standardize spot counting, aiming to eliminate the inter-operator variability inherent in manual microscopy. This shift is particularly critical for high-throughput FluoroSpot assays where differentiating overlapping spectral signals requires advanced computational deconvolution. The commercial viability of these digital tools is evident in the financial performance of key industry players who are monetizing this digital transformation. According to Revvity, Inc., February 2025, in the 'Annual Report for Fiscal Year Ending 12/29, 2024', the company's Life Sciences segment reported an increase of $22.5 million in software revenue, highlighting the surging customer investment in digital analysis platforms that streamline complex immunological workflows.

The widespread adoption of Multiplex FluoroSpot for polyfunctional immune profiling represents a definitive technical evolution over traditional single-analyte ELISpot methods. Researchers are prioritizing assays that can simultaneously detect multiple cytokines from a single cell, allowing for the granular characterization of T-cell polyfunctionality which is a superior correlate of protection in infectious disease and oncology studies. This demand for high-content data is driving sustained revenue growth for manufacturers specializing in protein analysis tools. According to Bio-Techne, August 2025, in the 'Bio-Techne Releases Fourth Quarter Fiscal 2025 Results' press release, the Protein Sciences segment achieved net sales of $226.5 million, an increase of 6% compared to the previous year, underscoring the robust market appetite for multiplex reagents and assay platforms essential for multi-parametric immune monitoring.

Key Market Players

• Becton, Dickinson and Company
• U-CyTech BV
• Cellular Technology Limited
• Mabtech AB
• Abcam Limited
• AID AUTOIMMUN DIAGNOSTIKA GMBH
• Mikrogen GmbH
• Bio-Connect Group
• Oxford Immunotec USA, Inc.
• Bio-Techne Corporation

Report Scope

In this report, the Global ELISpot and FluoroSpot Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

ELISpot and FluoroSpot Assay Market, By Product

• Assay Kits
• Analyzers
• Ancillary Products

ELISpot and FluoroSpot Assay Market, By Application

• Diagnostic
• Research

ELISpot and FluoroSpot Assay Market, By End user

• Hospitals & Clinics
• Research Institutes
• Biopharmaceutical Companies
• CROs

ELISpot and FluoroSpot Assay Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global ELISpot and FluoroSpot Assay Market.

Available Customizations:

Global ELISpot and FluoroSpot Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global ELISpot and FluoroSpot Assay Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Assay Kits, Analyzers, Ancillary Products)
  • 5.2.2. By Application (Diagnostic, Research)
  • 5.2.3. By End user (Hospitals & Clinics, Research Institutes, Biopharmaceutical Companies, CROs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America ELISpot and FluoroSpot Assay Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States ELISpot and FluoroSpot Assay Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada ELISpot and FluoroSpot Assay Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico ELISpot and FluoroSpot Assay Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End user

7. Europe ELISpot and FluoroSpot Assay Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany ELISpot and FluoroSpot Assay Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End user
  • 7.3.2. France ELISpot and FluoroSpot Assay Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom ELISpot and FluoroSpot Assay Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy ELISpot and FluoroSpot Assay Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain ELISpot and FluoroSpot Assay Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End user

8. Asia Pacific ELISpot and FluoroSpot Assay Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China ELISpot and FluoroSpot Assay Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End user
  • 8.3.2. India ELISpot and FluoroSpot Assay Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan ELISpot and FluoroSpot Assay Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea ELISpot and FluoroSpot Assay Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia ELISpot and FluoroSpot Assay Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End user

9. Middle East & Africa ELISpot and FluoroSpot Assay Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia ELISpot and FluoroSpot Assay Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE ELISpot and FluoroSpot Assay Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa ELISpot and FluoroSpot Assay Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End user

10. South America ELISpot and FluoroSpot Assay Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil ELISpot and FluoroSpot Assay Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia ELISpot and FluoroSpot Assay Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina ELISpot and FluoroSpot Assay Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global ELISpot and FluoroSpot Assay Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Becton, Dickinson and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. U-CyTech BV
• 15.3. Cellular Technology Limited
• 15.4. Mabtech AB
• 15.5. Abcam Limited
• 15.6. AID AUTOIMMUN DIAGNOSTIKA GMBH
• 15.7. Mikrogen GmbH
• 15.8. Bio-Connect Group
• 15.9. Oxford Immunotec USA, Inc.
• 15.10. Bio-Techne Corporation

16. Strategic Recommendations

17. About Us & Disclaimer